When analysed within the different tumour budding subgroups (Bd1/2/3), SATB2 showed a weak prognostic relevance in tumours with a low tumour budding activity (e.g., DSS: SATB2-high 110.2 months vs. SATB2-low/absent 104.4 months p = 0.05) and especially a strong prognostic impact within CRCs with a high tumour budding activity, where CRCs with a low/absent SATB2 expression showed a significantly worse survival rate compared to SATB2-high carcinomas (e.g., DSS: SATB2-high 51.1 months vs. SATB2-low/absent 29 months, p = 0.002) (Figure 3, Table S3). The gene discussed is SATB2; the disease is carcinoma.